BACKGROUND: Flow diversion is an established technique for treatment of cerebral aneurysms. The Pipeline embolization device (PED) is the only FDA-approved flow diverting stent in the USA. A second-generation device, PED Flex, has recently been released with modifications to the delivery system. Published reports of experience with this new device are limited. OBJECTIVE: To describe the initial outcomes from the first North American series using the PED Flex-a single-center experience of 44 cases. METHODS: All patients consecutively treated with the PED Flex embolization device from February 2015 through April 2015 were included in the study. Data were collected for patient demographics, aneurysm characteristics, technical procedural details, and early outcomes. RESULTS: PED Flex treatment was attempted in 42 patients (mean 56.6±2.0 years) with 44 aneurysms (mean size 6.5±0.6 mm), 41/44 (93%) of which were anterior circulation and 3/44 (7%) were posterior circulation. PED Flex was successfully implanted in 43/44 cases (98%). A single device was used in 41/43 cases (95%), with a mean of 1.07±0.05 devices implanted per case. Resheathing was performed in 4/44 cases (9%). Mean postprocedure hospital length of stay was 1.3±0.2 days. One significant neurological complication (2.3%) occurred, which was a stroke in a patient non-compliant with the prescribed antiplatelet regimen. CONCLUSIONS: Pipeline Flex is a second-generation flow diverter with enhanced features compared with the first-generation PED. These modifications allow for more reliable deployment with continued improvements in procedural safety. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND: Flow diversion is an established technique for treatment of cerebral aneurysms. The Pipeline embolization device (PED) is the only FDA-approved flow diverting stent in the USA. A second-generation device, PED Flex, has recently been released with modifications to the delivery system. Published reports of experience with this new device are limited. OBJECTIVE: To describe the initial outcomes from the first North American series using the PED Flex-a single-center experience of 44 cases. METHODS: All patients consecutively treated with the PED Flex embolization device from February 2015 through April 2015 were included in the study. Data were collected for patient demographics, aneurysm characteristics, technical procedural details, and early outcomes. RESULTS: PED Flex treatment was attempted in 42 patients (mean 56.6±2.0 years) with 44 aneurysms (mean size 6.5±0.6 mm), 41/44 (93%) of which were anterior circulation and 3/44 (7%) were posterior circulation. PED Flex was successfully implanted in 43/44 cases (98%). A single device was used in 41/43 cases (95%), with a mean of 1.07±0.05 devices implanted per case. Resheathing was performed in 4/44 cases (9%). Mean postprocedure hospital length of stay was 1.3±0.2 days. One significant neurological complication (2.3%) occurred, which was a stroke in a patient non-compliant with the prescribed antiplatelet regimen. CONCLUSIONS: Pipeline Flex is a second-generation flow diverter with enhanced features compared with the first-generation PED. These modifications allow for more reliable deployment with continued improvements in procedural safety. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Geoffrey P Colby; Li-Mei Lin; Risheng Xu; Narlin Beaty; Matthew T Bender; Bowen Jiang; Judy Huang; Rafael J Tamargo; Alexander L Coon Journal: Interv Neurol Date: 2017-02-03
Authors: D Atasoy; N Kandasamy; J Hart; J Lynch; S-H Yang; D Walsh; C Tolias; T C Booth Journal: AJNR Am J Neuroradiol Date: 2019-11-14 Impact factor: 3.825
Authors: Brian P Walcott; Clemens Reinshagen; Christopher J Stapleton; Omar Choudhri; Vitaliy Rayz; David Saloner; Michael T Lawton Journal: J Cereb Blood Flow Metab Date: 2016-03-23 Impact factor: 6.200
Authors: Josser E Delgado Almandoz; Yasha Kayan; Andrea Tenreiro; Adam N Wallace; Jill M Scholz; Jennifer L Fease; Anna M Milner; Maximilian Mulder; Kyle M Uittenbogaard; Oscar Tenreiro-Picón Journal: Neuroradiology Date: 2017-10-06 Impact factor: 2.804